Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GeneDx Holdings Corp. - Class A Common Stock (NQ: WGS )

1.740 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 4, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about GeneDx Holdings Corp. - Class A Common Stock

< Previous 1 2 Next >
GeneDx Presents New Data at the American Epilepsy Society Annual Meeting Demonstrating That Exome Sequencing Outperforms Multi-Gene Panels for Patients with Epilepsy
New research from one of the largest exome sequencing studies of patients with epilepsy adds to the mounting evidence that exome sequencing offers superior clinical results compared to multi-gene... 
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx to Participate in 6th Annual Evercore ISI HealthCONx Conference
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Reports Third Quarter 2023 Financial Results and Business Highlights
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx to Report Third Quarter 2023 Financial Results on Monday, October 30, 2023
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Announces Evolution of Executive Leadership Team
Melanie Duquette joining team as Chief Growth Officer to drive commercial excellence, Jennifer Brendel to take new role as Chief of Corporate Affairs amplifying the GeneDx brand and leadership... 
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Announces Industry-Leading Accomplishment of 500,000 Clinical Exomes Sequenced
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Announces Data Demonstrating that Whole Exome and Genome Sequencing Report Fewer Variants of Uncertain Significance (VUS) than Multi-Gene Panel Testing Published in Genetics in Medicine
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Reports Second Quarter 2023 Financial Results and Business Highlights
From GeneDx Holdings Corp.
Via GlobeNewswire
PacBio and GeneDx Launch Research Collaboration with the University of Washington to Study Long-Read Whole Genome Sequencing for Increased Diagnostic Yield in Neonatal Care
Study is first of its kind to compare diagnostic rates across short- and long-read sequencing platforms 
From GeneDx Holdings Corp.; PacBio
Via GlobeNewswire
GeneDx and Prognos Health Announce Strategic Partnership to Help Rare Disease Patients More Rapidly Gain Access to Potential Treatment Options
Partnership allows commercial biopharma companies to leverage real-time data within comprehensive Prognos Marketplace to provide available treatment options for patients 
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx to Present New Data on Urine Mitochondrial DNA Testing at the 2023 United Mitochondrial Disease Foundation’s Mitochondrial Medicine Symposium
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Announces New Tool to Help Harness Human Pangenome Diversity for Clinical Interpretation of Variants
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Commends the States of Arizona and Florida for Adding Rapid Whole Genome Sequencing (rWGS) as a Covered Benefit for Medicaid Pediatric Patients
Eight state Medicaid programs now cover rWGS in the pediatric inpatient setting, with active bills in other states 
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx to Participate in Upcoming Investor Conferences in June
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx to Participate in World Orphan Drug Congress Keynote and Panel Presentations
Keynote session to highlight value of GeneDx genomic data and clinical insights to accelerate genetic neurodevelopmental disorder pipeline for Mahzi Therapeutics 
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Regains Compliance with Nasdaq Minimum Bid Price Requirement
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Reports First Quarter 2023 Financial Results and Business Highlights
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Adds Buccal Swab as Non-Invasive Whole Genome Sequencing Sample Collection Option
New Option Enables Easier DNA Sample Collection from Biological Parents to Aid in Disease Diagnosis 
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Announces Clarification Regarding CUSIP Number for Public Warrant Holders
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Announces Reverse Stock Split
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx to Report First Quarter 2023 Financial Results on Tuesday, May 9, 2023
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Appoints Devin K. Schaffer, J.D., M.B.A, as General Counsel
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey”
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Presents New Data at ACMG Demonstrating the Benefits of Exome Sequencing Over Chromosomal Microarray
New research released at ACMG Annual Clinical Genetics Meeting reiterates the superiority of exome sequencing’s role in shortening the diagnostic odyssey 
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx to Participate in the Cowen 43rd Annual Healthcare Conference
From GeneDx Holdings Corp.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.